Posts by: Marisa Wexler

Marisa Wexler

July 16, 2019July 16, 2019

Independent Mouse Study Reinforces Remyelinating Potential of ISP Therapy

News

A new study demonstrates that intracellular sigma peptide (ISP) can promote remyelination in a mouse model of multiple sclerosis (MS). Importantly, this study was independent of NervGen, a pharmaceutical ... Read more

June 25, 2019June 25, 2019

New Jersey Health Foundation Awards $70,000 to Kessler Foundation Researchers Studying MS and Stroke

News

Two researchers at Kessler Foundation were awarded grants of $35,000 each by the New Jersey Health Foundation to pursue their investigations into new ways to improve rehabilitative care for ... Read more

June 24, 2019June 24, 2019

Blocking Sortilin Protein May Be Potential Treatment for Chronic Nerve Pain, Mouse Study Suggests

News

Inhibiting the function of a protein called sortilin — an important regulator of nerve damage-induced pain in mice — may represent a potentially effective strategy for treating chronic pain ... Read more

June 20, 2019June 20, 2019

Potential Mechanism Behind Effectiveness of B-cell Depletion Therapy in MS Uncovered

News

The loss of immune B-cells, and the resulting changes in the profile of immune T-cells, is a major mechanism of action for the beneficial effects seen with ublituximab treatment ... Read more

June 20, 2019June 20, 2019

Childhood MS Linked to Greater Cognitive Impairment in Adulthood, Study Finds

News

People with pediatric-onset multiple sclerosis (POMS) have a greater decline in cognitive function, and are more likely to experience cognitive impairment in adulthood, than those whose disease began when ... Read more

June 13, 2019June 13, 2019

Elevated Blood Pressure May Predict Brain Bleeding in RRMS Patients Treated with Lemtrada, Study Suggests

News

New research suggests that rising blood pressure might be predictive of intracranial hemorrhage — bleeding in the brain, a serious and sometimes fatal condition — in people with multiple ... Read more

June 12, 2019June 12, 2019

Biotech Startup Receives Funding to Pursue Cell-based Therapies for Neurological Disorders

News

Startup company Oscine Therapeutics has received an investment from Sana Biotechnology to support the research and development of cell-based therapies for a variety of neurological disorders, including multiple sclerosis ... Read more

June 11, 2019June 11, 2019

Study Identifies Possible Genetic Causes of MS

News

Scientists are zeroing in on mutations in a few genes that appear to be major risk factors for developing multiple sclerosis (MS). The results of their research suggest there ... Read more

June 6, 2019June 6, 2019

Roche, Sutter Health Testing Floodlight Mobile App That Monitors Patients’ MS

News

Sutter Health, a California-based healthcare group, has partnered with the biotechnology company Roche to test a new mobile app that aims to improve monitoring of symptoms in people who ... Read more

May 29, 2019May 29, 2019

Celgene and MS Association of America Collaborating to Boost Knowledge on Brain Health in MS

News

Biopharmaceutical company Celgene has teamed up with the Multiple Sclerosis Association of America (MSAA) to launch a new initiative called MS MindShift: A New View of MS, aimed at ... Read more

May 20, 2019May 20, 2019

#AANAM — Evobrutinib Continues to Show Potential for MS, 48-week Phase 2 Data Suggest

News

Investigational therapy evobrutinib, also known as M2951, can reduce relapse rates and brain lesions in people with relapsing forms of multiple sclerosis (MS), 48-week data from a Phase 2 clinical ... Read more

May 16, 2019May 16, 2019

#AANAM — Gut Bacteria May Play Role in Pediatric MS, Studies Suggest

News

As strange as it is to think about, many bacteria live in the human body, most of which are found in the gut (often referred to as the gut ... Read more

May 15, 2019June 27, 2019

#AANAM – Biogen Offers Update on Development Plans for MS Therapies

News

At the 2019 annual meeting of the American Academy of Neurology (AAN), Multiple Sclerosis News Today sat down with Bernd Kieseier, MD, global head of multiple sclerosis at Biogen, to discuss ... Read more

May 13, 2019May 13, 2019

#AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest

News

Early, one-year data from the Phase 3 CHORDS study show that Ocrevus effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying ... Read more

May 10, 2019May 10, 2019

#AANAM – Interferon Beta Exposure Does Not Seem to Increase Risk of Pregnancy Complications, Study Suggests

News

Exposure to interferon beta does not seem to increase the risk of complications during pregnancy in women with multiple sclerosis (MS), new research suggests. The data were presented in ... Read more

May 8, 2019May 8, 2019

#AANAM – Research Suggests Extended Interval Dosing of Tysabri Can Decrease Risk of PML

News

New data suggests that treatment with Tysabri (natalizumab) in an extended interval dosing regimen is associated with a significantly lower risk of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), compared ... Read more

May 8, 2019May 17, 2019

#AANAM – Research Suggests Misconceptions About MS Risk in Pregnant Women

News

New research suggests that even though pregnant women with multiple sclerosis are often viewed as high-risk by their physicians, pregnancy  does not seem to increase the likelihood of adverse ... Read more

May 6, 2019May 6, 2019

#AANAM – IV Therapy May Be More Effective Than Oral Treatment in Younger RRMS Patients, Research Suggests

News

Infusible disease-modifying treatment — that is, therapies given intravenously — might have greater benefits for younger people with multiple sclerosis (MS) than oral ones, new research suggests. The research ... Read more

May 6, 2019May 6, 2019

#AANAM — DMTs Primarily Responsible for Rising Healthcare Costs for MS Patients, Study Suggests

News

A trend of rapidly increasing costs for disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) appear to be the primary driver behind the overall rise in healthcare costs ... Read more

May 3, 2019May 6, 2019

#AANAM – Precision Innovative Network and Splice Machine Will Present Predictive Healthcare Application at AAN Meeting

News

A new clinical application prototype that uses machine learning to help physicians predict the best treatment options for patients with multiple sclerosis (MS) will be unveiled at the American Academy ... Read more

April 26, 2019June 3, 2019

Cellular Senescence Implicated in MS Development, Study Suggests

News

Cellular senescence — the process of aging at the cellular level — may play a role in the development of primary progressive multiple sclerosis (PPMS) by limiting the ability ... Read more

April 15, 2019April 18, 2019

Web Portal That Detects Cognitive Changes via Language Tests Detailed in Study

News

A new web portal called Talk2Me that detects early changes in language could help doctors diagnose or determine progression in neurodegenerative disorders like multiple sclerosis, the scientists who created it ... Read more

April 12, 2019April 18, 2019

Excess Body Fat Spurs Disease Progression by Impact on Immune Cells, Study Suggests

News

A link between fat molecules called ceramides and worsening disease in overweight and obese people with multiple sclerosis appears to exist, a study reports, with its findings suggesting that ceramides prompt ... Read more

April 4, 2019April 4, 2019

CMSC Announces Technology Contests to Improve MS Patients’ Quality Of Life

News

The Consortium of Multiple Sclerosis Centers (CMSC) announced two contests that will be featured at its Annual Meeting, May 28–June 1 in Seattle, Washington. The contests, called “Design for Rehabilitation — Take ... Read more

April 3, 2019April 8, 2019

Cleveland Clinic Neurologist Applauds Mayzent’s FDA Approval, But Surprised by Those It May Not Treat

News

When the U.S. Food and Drug Administration approved the disease-modifying therapy Mayzent for relapsing types of multiple sclerosis, it specified in its label that the treatment was for people with clinically isolated syndrome, relapsing-remitting ... Read more

March 25, 2019March 25, 2019

Body Mass Index, but Not Age at Puberty, Linked to Higher MS Risk, Study Suggests

News

Body mass index (BMI), but not the age at which people start puberty, could increase the risk of multiple sclerosis (MS), a study suggests. The study, “Effect of age ... Read more